Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.74 |
| ▸ | RAB9A | P51151 | 2/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.74 |
| ▸ | EGFR | P00533 | 8/20 | 0.66 |
| ▸ | MMP1 | P03956 | 7/20 | 0.66 |
| ▸ | MMP2 | P08253 | 7/20 | 0.66 |
| ▸ | MMP9 | P14780 | 7/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.61 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.61 |
| ▸ | MAOB | P27338 | 3/20 | 0.60 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5046634 | 1.00 | NPC1 (0.74) | NPC1RAB9ASMN1; SMN2EGFRMMP1 | |
| SCHEMBL14096607 | 0.86 | KMT2A (0.68) | NPC1RAB9ASMN1; SMN2ALDH1A1CYP1A2 | |
| SCHEMBL7813844 | 0.84 | ALDH1A1 (0.64) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL7813846 | 0.84 | ALDH1A1 (0.64) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL10492426 | 0.84 | MMP1 (0.80) | NPC1RAB9AEGFRMMP1MMP2 | |
| SCHEMBL10492424 | 0.84 | MMP1 (0.80) | NPC1RAB9AEGFRMMP1MMP2 | |
| N-(2-Fluorophenyl)Cinnamamide SCHEMBL1967609 | 0.80 | MMP1 (1.00) | NPC1RAB9AEGFRMMP1MMP2 | |
| N-(2-Fluorophenyl)Cinnamamide SCHEMBL1967607 | 0.80 | MMP1 (1.00) | NPC1RAB9AEGFRMMP1MMP2 | |
| SCHEMBL11873425 | 0.78 | SMN1; SMN2 (0.53) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL29505834 | 0.78 | SMN1; SMN2 (0.53) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9765030-B2 | Benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2017-09-19 | — | — | US | disclosed |
| EP-1981342-B1 | SELECTIVE BENZYLAMINE DERIVATIVES AND THEIR UTILITY AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | REDDYS LAB LTD DR (IN) | 2016-11-30 | — | — | EP | disclosed |
| US-20140134235-A1 | NOVEL BENZYLAMINE DERIVATIVES AND THEIR UTILITY AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2014-05-15 | — | — | US | disclosed |
| US-8604055-B2 | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2013-12-10 | — | — | US | disclosed |
| CN-101448397-B | Selective benzylamine derivatives and their use as cholesteryl ester transfer protein inhibitors | REDDYS LAB LTD DR | 2013-04-24 | — | — | CN | disclosed |
| CN-101448397-A | Selective benzylamine derivatives and their use as cholesteryl ester transfer protein inhibitors | REDDY US THERAPEUTICS INC (US) | 2009-06-03 | — | — | CN | disclosed |
| EP-1981342-A1 | SELECTIVE BENZYLAMINE DERIVATIVES AND THEIR UTILITY AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | Reddy US Therapeutics, Inc. (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007075194-A1 | SELECTIVE BENZYLAMINE DERIVATIVES AND THEIR UTILITY AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | REDDY US THERAPEUTICS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070015758-A1 | Novel benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140134235-A1 | NOVEL BENZYLAMINE DERIVATIVES AND THEIR UTILITY AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | CETP, NPC1, DBI | NPC1 2/4885RAB9A 1430/4885SMN1; SMN2 3792/4885 |
| US-20070015758-A1 | Novel benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors | CETP, NPC1, DBI | NPC1 2/4885RAB9A 1430/4885SMN1; SMN2 3792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.